Tonix Pharmaceuticals Receives FDA Approval for Fibromyalgia Treatment Tonmya
PorAinvest
viernes, 15 de agosto de 2025, 4:34 pm ET1 min de lectura
TNXP--
Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S., predominantly women. The condition is characterized by chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness, among other symptoms. Tonmya, a first-in-class, non-opioid, once-daily bedtime analgesic, is designed to provide rapid absorption into the bloodstream via a unique sublingual formulation [1].
The FDA approval is based on the results of two pivotal Phase 3 clinical trials, RELIEF and RESILIENT, which enrolled nearly 1,000 patients in total. Both trials demonstrated that Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint. Additionally, a greater percentage of participants taking Tonmya experienced clinically meaningful improvement in their pain after three months [1].
Tonmya was generally well tolerated, with the most common adverse events including oral hypoesthesia, oral discomfort, and somnolence. The drug is expected to be commercially available in the fourth quarter of 2025 [1].
Tonix Pharmaceuticals, a fully-integrated biotechnology company, will host a webcast and conference call on Monday, August 18, 2025, at 8:30 AM ET to discuss the approval of Tonmya. For more information, visit TonmyaHCP.com [1].
References:
[1] https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-fda-approval-194400374.html
Tonix Pharmaceuticals has received FDA approval for Tonmya, a cyclobenzaprine sublingual tablet for fibromyalgia treatment. Tonmya is the first new treatment for the condition in over 15 years. It is taken sublingually and has shown promise in reducing pain and improving function in patients with fibromyalgia.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has announced that the U.S. Food and Drug Administration (FDA) has approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. This approval marks the first new FDA-approved therapy for fibromyalgia in over 15 years [1].Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S., predominantly women. The condition is characterized by chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness, among other symptoms. Tonmya, a first-in-class, non-opioid, once-daily bedtime analgesic, is designed to provide rapid absorption into the bloodstream via a unique sublingual formulation [1].
The FDA approval is based on the results of two pivotal Phase 3 clinical trials, RELIEF and RESILIENT, which enrolled nearly 1,000 patients in total. Both trials demonstrated that Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint. Additionally, a greater percentage of participants taking Tonmya experienced clinically meaningful improvement in their pain after three months [1].
Tonmya was generally well tolerated, with the most common adverse events including oral hypoesthesia, oral discomfort, and somnolence. The drug is expected to be commercially available in the fourth quarter of 2025 [1].
Tonix Pharmaceuticals, a fully-integrated biotechnology company, will host a webcast and conference call on Monday, August 18, 2025, at 8:30 AM ET to discuss the approval of Tonmya. For more information, visit TonmyaHCP.com [1].
References:
[1] https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-fda-approval-194400374.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios